rewrite this title iRhythm Stock: Revenue Growth Does Not Miss a Beat – Nanalyze

There are thousands of technology stocks, but we currently track about 400 in our Nanalyze Disruptive Tech catalog, so we can focus the ADHD energy of our MBAs. We have written multiple articles on most, if not all, of these tech stocks. This continuity enables us to track progress or the lack thereof across the years – and to see what we got right and what we got wrong. For instance, a couple months ago, we detailed TransMedics’ significant and seemingly successful shift from a medical device company to a logistics provider for the organ transplant industry. Previously, we had voiced considerable doubt regarding this new business model and the company’s capacity to sustain revenue growth. 

Another medical device company in our catalog, long overdue for analysis, is iRhythm (IRTC), which has developed a wearable biosensor that uses artificial intelligence to monitor patients and diagnose heart arrhythmias. Initially, we viewed it as a narrow play on cardiac monitoring and AI back in 2019. In a 2021 follow-up, the total addressable market (TAM) seemed too small, and we already held shares in larger, more diverse medical device companies. However, in 2023, iRhythm